Real-world cohort shows that efgartigimod improves symptoms in patients intolerant to IVIg, suggesting a new treatment pathway.
In this real-world cohort, efgartigimod demonstrated a rapid and meaningful clinical benefit with a favorable tolerability profile in patients with AChR-positive gMG after IVIg failure or intolerance. These findings support the potential role of EFG as an effective therapeutic option in this difficult-to-treat population.
No takes yet. Share an insight, caveat, or question.
D’Amico et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: